Corcept Therapeutics Incorporated

Total Valuation

Corcept Therapeutics Incorporated carries a market capitalization of 12.07B, placing it among publicly traded companies globally. Its enterprise value stands at 9.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Corcept Therapeutics Incorporated currently has 107.92M shares outstanding.

Valuation Ratios

Corcept Therapeutics Incorporated trades at a trailing price-to-earnings ratio of 164.29. The price-to-sales ratio is 10.91, and the price-to-book ratio stands at 13.30.

Enterprise Valuation

On an enterprise value basis, Corcept Therapeutics Incorporated trades at an EV/EBITDA multiple of 1,029.46 and an EV/FCF ratio of 80.77. The EV/Sales ratio of 10.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,418.42 provides insight into valuation relative to core operating earnings.

Financial Position

Corcept Therapeutics Incorporated maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Corcept Therapeutics Incorporated has paid -28.81M in income taxes, reflecting an effective tax rate of 6.41.

Stock Price Statistics

Corcept Therapeutics Incorporated's stock has gained approximately 60.90529% over the past 52 weeks. The 50-day moving average sits at 103.54, while the 200-day moving average is 66.63.

Income Statement

Over the trailing twelve months, Corcept Therapeutics Incorporated generated 830.81M in revenue and converted that into 55.18M in net income, yielding earnings per share of 0.48. EBITDA reached 8.83M, while operating income came in at 6.41M.

Balance Sheet

Corcept Therapeutics Incorporated holds 308.20M in cash and equivalents against 9.42M in total debt, resulting in a net debt position of -111.04M. Total book value stands at 705.78M, with working capital of 285.87M providing operational flexibility.

Cash Flow

Corcept Therapeutics Incorporated produced 109.70M in operating cash flow over the past twelve months. After subtracting -2.78M in capital expenditures, free cash flow totaled 106.92M - equivalent to 1.03 per share.

Margins

Corcept Therapeutics Incorporated operates with a gross margin of 98.30, reflecting its pricing power and cost economics. The operating margin of 0.77 and net profit margin of 6.64 provide insight into operational efficiency.

Dividends & Yields

Scores

Corcept Therapeutics Incorporated posts an Altman Z-Score of 33.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.